WO2005118840A3 - Diagnostics and therapeutics for diseases associated with kallikrein 10 (klk10) - Google Patents

Diagnostics and therapeutics for diseases associated with kallikrein 10 (klk10) Download PDF

Info

Publication number
WO2005118840A3
WO2005118840A3 PCT/EP2005/005782 EP2005005782W WO2005118840A3 WO 2005118840 A3 WO2005118840 A3 WO 2005118840A3 EP 2005005782 W EP2005005782 W EP 2005005782W WO 2005118840 A3 WO2005118840 A3 WO 2005118840A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
klk10
diseases
kallikrein
therapeutics
Prior art date
Application number
PCT/EP2005/005782
Other languages
French (fr)
Other versions
WO2005118840A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2005118840A2 publication Critical patent/WO2005118840A2/en
Publication of WO2005118840A3 publication Critical patent/WO2005118840A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

The invention provides a human KLK10 which is associated with the endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, muscle-skeleton disorders, cardiovascular disorders, neurological disorders, urological disorders, respiratory diseases and reproduction disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, muscle-skeleton disorders, cardiovascular disorders, neurological disorders, urological disorders, respiratory diseases and reproduction disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of KLK10 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/005782 2004-06-03 2005-05-30 Diagnostics and therapeutics for diseases associated with kallikrein 10 (klk10) WO2005118840A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04013108 2004-06-03
EP04013108.8 2004-06-03

Publications (2)

Publication Number Publication Date
WO2005118840A2 WO2005118840A2 (en) 2005-12-15
WO2005118840A3 true WO2005118840A3 (en) 2006-05-18

Family

ID=34981926

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/005782 WO2005118840A2 (en) 2004-06-03 2005-05-30 Diagnostics and therapeutics for diseases associated with kallikrein 10 (klk10)

Country Status (1)

Country Link
WO (1) WO2005118840A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002037112A2 (en) 2000-11-01 2002-05-10 Mount Sinai Hospital Detection of ovarian cancer
US7598052B2 (en) * 2005-10-11 2009-10-06 The Regents Of The University Of Michigan Expression profile of thyroid cancer
KR101920158B1 (en) 2017-06-27 2018-11-19 강원대학교산학협력단 Methylation marker for diagnosing chronic obstructive pulmonary disease
WO2021062012A1 (en) * 2019-09-25 2021-04-01 Emory University Use of klk10 and engineered derivatizations thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039175A1 (en) * 1995-06-06 1996-12-12 New England Medical Center Hospitals, Inc. Nes-1 polypeptides, dna, and related molecules and methods
WO2002102235A2 (en) * 2001-06-18 2002-12-27 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039175A1 (en) * 1995-06-06 1996-12-12 New England Medical Center Hospitals, Inc. Nes-1 polypeptides, dna, and related molecules and methods
WO2002102235A2 (en) * 2001-06-18 2002-12-27 Eos Biotechnology Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DHAR S ET AL: "Analysis of normal epithelial cell specific-1 (NES1)/kallikrein 10 mRNA expression by in situ hybridization, a novel marker for breast cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. NOV 2001, vol. 7, no. 11, November 2001 (2001-11-01), pages 3393 - 3398, XP002348128, ISSN: 1078-0432 *
GOYAL J ET AL: "THE ROLE FOR NES1 SERINE PROTEASE AS A NOVEL TUMOR SUPPRESSOR", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 58, no. 21, 1 November 1998 (1998-11-01), pages 4782 - 4786, XP001094008, ISSN: 0008-5472 *
LUO L-Y ET AL: "EXPRESSION OF THE NORMAL EPITHELIAL CELL-SPECIFIC 1 (NES1; KLK10) CANDIDATE TUMOUR SUPPRESSOR GENE IN NORMAL AND MALIGNANT TESTICULAR TISSUE", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 85, no. 2, 20 July 2001 (2001-07-20), pages 220 - 224, XP001098019, ISSN: 0007-0920 *
LUO L-Y ET AL: "THE SERUM CONCENTRATION OF HUMAN KALLIKREIN 10 REPRESENTS A NOVEL BIOMARKER FOR OVARIAN CANCER DIAGNOSIS AND PROGNOSIS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 63, no. 4, 15 February 2003 (2003-02-15), pages 807 - 811, XP001182632, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2005118840A2 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
WO2005075665A3 (en) Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
WO2006008002A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 1 (klk1)
WO2005106492A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3)
WO2004104216A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
WO2004104215A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase 7 (dpp7)
WO2005118840A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 10 (klk10)
WO2005078117A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 6 (klk6)
WO2005106471A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
WO2005075662A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)
WO2004097358A3 (en) Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
WO2005022164A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2006008008A3 (en) Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a)
WO2005095984A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled alpha 2a-adrenoceptor (adra2a)
WO2004106536A3 (en) Diagnostics and therapeutics for diseases associated with serine protease 8 (prss8)
WO2004080374A3 (en) Diagnostics and therapeutics for diseases associated with phosphodi-esterase 1c (pde1c)
WO2004081563A3 (en) Diagnostics and therapeutics for diseases associated with phosphodiesterase 1a (pde1a)
WO2004099783A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2005108998A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor beta-3 adreno (adrb3)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2004106935A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 103 (gpr103)
WO2005040829A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17)
WO2005103690A3 (en) Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)
WO2004104595A3 (en) Diagnostics and therapeutics for diseases associated with x-pro dipeptidase (pepd)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase